Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR7390 in Advanced Solid Tumors
NCT02968485Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Nov 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR7390 in solid tumor, sponsored by Hengrui. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
SHR7390
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02968485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968485.